IMNM · Immunome, Inc.

Immunome's Q1 2026 results reflect intensified R&D investment at $46.4 million, up from $36.9 million year-over-year, driven by advancement of its oncology pipeline including the pivotal NDA submission for varegacestat. The net loss widened to $53.8 million from $41.6 million in Q1 2025, with EPS improving slightly to $(0.48) from $(0.52) due to increased shares outstanding to 113 million from 79 million. G&A expenses rose to $13.0 million, incorporating $4.2 million in stock-based compensation. Despite the loss, a robust $582.7 million cash position as of March 31 provides runway into 2028, supporting ongoing and planned trials. CEO Clay Siegall highlighted the NDA as a key milestone for desmoid tumor patients, complemented by detailed Phase 3 RINGSIDE data at ASCO showing superior PFS, ORR, and tumor reduction versus placebo, with a favorable safety profile. Pipeline momentum includes IM-1021 Phase 1 progress with lymphoma responses, IM-3050 site initiation, IM-1617 IND clearance for Q2 start, and upcoming INDs for IM-1340 and IM-1335, positioning Immunome as a multi-program ADC player.